A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis
Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Gastrointestinal Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/9679287 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850228398155104256 |
|---|---|
| author | Dean Ehrlich Nimah Jamaluddin Joseph Pisegna David Padua |
| author_facet | Dean Ehrlich Nimah Jamaluddin Joseph Pisegna David Padua |
| author_sort | Dean Ehrlich |
| collection | DOAJ |
| description | Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. There are no guidelines regarding biologic salvage therapy for IBD in the setting of active treatment with another biologic agent. After waiting one half-life of secukinumab, our patient had an excellent response to initiation of infliximab. |
| format | Article |
| id | doaj-art-2b53b2c3b9a84a91a15ecc71563b3191 |
| institution | OA Journals |
| issn | 2090-6528 2090-6536 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Gastrointestinal Medicine |
| spelling | doaj-art-2b53b2c3b9a84a91a15ecc71563b31912025-08-20T02:04:33ZengWileyCase Reports in Gastrointestinal Medicine2090-65282090-65362018-01-01201810.1155/2018/96792879679287A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing SpondylitisDean Ehrlich0Nimah Jamaluddin1Joseph Pisegna2David Padua3Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USADivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USADivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USADivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USASecukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. There are no guidelines regarding biologic salvage therapy for IBD in the setting of active treatment with another biologic agent. After waiting one half-life of secukinumab, our patient had an excellent response to initiation of infliximab.http://dx.doi.org/10.1155/2018/9679287 |
| spellingShingle | Dean Ehrlich Nimah Jamaluddin Joseph Pisegna David Padua A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis Case Reports in Gastrointestinal Medicine |
| title | A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis |
| title_full | A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis |
| title_fullStr | A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis |
| title_full_unstemmed | A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis |
| title_short | A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis |
| title_sort | challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis |
| url | http://dx.doi.org/10.1155/2018/9679287 |
| work_keys_str_mv | AT deanehrlich achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis AT nimahjamaluddin achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis AT josephpisegna achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis AT davidpadua achallengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis AT deanehrlich challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis AT nimahjamaluddin challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis AT josephpisegna challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis AT davidpadua challengingcaseofsevereulcerativecolitisfollowingtheinitiationofsecukinumabforankylosingspondylitis |